Drugs · Brain health technique

GLP-1 Receptor Agonists

Evidence grade: Context Dependent

Illustration for GLP-1 Receptor Agonists

A class of injectable or oral medications that mimic the hormone glucagon-like peptide-1 (GLP-1) to improve insulin sensitivity, suppress appetite, and reduce inflammation. Includes semaglutide (Ozempic®, Wegovy®, Rybelsus®), liraglutide (Victoza®, Saxenda®), and tirzepatide (Mounjaro®, Zepbound®).

Practice
Drugs
Principle
Treatment
Tactic
Metabolic & Vascular Optimization Drugs
Evidence grade
Context Dependent
Strength of evidence
Medium

How to practice GLP-1 Receptor Agonists

Prescribed for type 2 diabetes, obesity, or metabolic syndrome. Typical dosing: once-weekly injection (semaglutide or tirzepatide) or daily injection (liraglutide). Combine with diet and activity modification. Common side effects: nausea, GI upset, constipation. Avoid in history of medullary thyroid cancer or pancreatitis. Not yet approved for cognitive prevention.

The evidence behind GLP-1 Receptor Agonists

GLP-1 is a hormone your gut naturally releases after you eat, and these drugs copy it. They help your pancreas release insulin when your blood sugar rises. They also slow how fast your stomach empties and turn down your appetite. Large clinical trials confirm strong benefits for your heart and metabolism. These include weight loss, better blood sugar control, and fewer cardiovascular events (e.g. heart attacks and strokes). This protection for your metabolism and blood vessels is key to preventing disease, and the evidence for it remains strong.

Impact on brain health

In your brain, these drugs may calm inflammation and improve how well neurons use glucose. Early studies suggested these drugs could slow cognitive decline by improving how brain cells respond to insulin and make energy. But two large trials of semaglutide in people who already had Alzheimer's found no slowing of decline in thinking or daily function over the trial period, so the evidence for a direct benefit to memory and thinking is now lower once the disease is established.

Reviewed by BetterBrain's clinical advisors · Updated November 2026 · Our science

Pair this with other habits from the same practice.

  • Evidence grade: Context Dependent

    Anti-Amyloid Monoclonal Antibodies

    FDA-approved biologic drugs that target beta-amyloid plaques to slow Alzheimer’s progression, including lecanemab (Leqembi®), donanemab (Kisunla™).

    Medium effort

  • Evidence grade: Context Dependent

    Antihypertensives

    Medications that lower blood pressure to protect vascular and brain health, including ACE inhibitors (lisinopril, enalapril), ARBs (losartan, valsartan), calcium channel blockers…

    Low effort · High cost

  • Evidence grade: Context Dependent

    Lipid-Lowering Drugs

    Therapies that reduce LDL cholesterol and vascular inflammation, including statins (atorvastatin, rosuvastatin, simvastatin), PCSK9 inhibitors (alirocumab, evolocumab), and ezetim…

    Low effort · High cost

See all 20 drugs techniques →

Take control of your brain health

BetterBrain gives you a personalized protocol of techniques like these, backed by science and tailored to you.

How BetterBrain worksSee pricing